Ticker News
$BMRA News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
BMRA Q1 FY2027: inFoods Medicare claims paid at $300; revenue $1.3M, loss $1.2M, cash $2.7M
Biomerica (NASDAQ: BMRA) reported Q1 FY2027: net sales ~$1.3M, gross profit ~$103k (8% margin), operating and net loss of approximately $1.2M, and cash of ~$2.7M after a $2.23M private placement. Commercially, inFoods® IBS is gaining Medicare traction — 100% of initial valid Medicare claims processed as of Oct 15 were paid at the full CMS rate of $300 and Medicare-related test orders rose 120% in September vs August — and the company engaged B. Riley to evaluate strategic opportunities while advancing CDM work with potential initial fees >$1.75M.
BMRA FY2026: revenue down, loss narrowed; $2.23M financing and Medicare reimbursement momentum for inFoods IBS
Biomerica reported FY2026 revenue of ~$4.5M (down from $5.3M) and a narrowed net loss of ~$3.8M; Q4 sales rose ~17% to ~$0.875M and quarterly net loss improved ~27%. The company highlighted commercialization progress for inFoods® IBS — 100% of initial valid Medicare claims processed to date were paid at the $300 CMS rate and a PLA CPT code exists — plus a $1.75M CDMO development engagement, first commercial orders/reorders for its H. pylori test, a $2.23M post-year private placement (no warrants), and engagement of B. Riley to evaluate strategic opportunities.
Biomerica private placement: 1.3937M shares at $1.60 to raise ~$2.23M
Biomerica agreed to sell 1,393,705 unregistered shares of common stock at $1.60 per share in a private placement expected to raise approximately $2.23 million; the financing includes no warrants. Participation included B. Riley Principal Capital, certain B. Riley executives, the CEO and all board members; issuance is tied to closing and the company says pro forma shares outstanding would be ~4,588,968 (new shares ≈30.4% of pro forma). Timing: The press release does not indicate dilution today. Earliest dilution: date unknown.
Biomerica Signs MSA for CDMO IVD Development; $1.75M Initial Target
Biomerica (BMRA) announced a Master Services Agreement with a confidential life‐sciences partner to develop proprietary in vitro diagnostic (IVD) assays, with an initial contract development target fee of over $1.75 million to be earned across multiple Statements of Work. All development will be performed at Biomerica's FDA‐licensed, ISO 13485‐certified facility using existing staff and equipment, with revenue recognized on milestone completion as deliverables are accepted, positioning the work as a capital‐light CDMO revenue stream while the company keeps its focus on inFoods® IBS. The $1.75M is an aggregate target across SOWs (not guaranteed revenue) and no revenue is recognized until individual SOWs are executed and milestones accepted; the partner's identity remains confidential.
BMRA signs $1.75M+ CDMO master services agreement to develop IVD assays
Biomerica (BMRA) signed a three-year CDMO Master Services Agreement with a confidential life sciences company to develop proprietary in vitro diagnostic assays, with an initial contract development target fee of over $1.75 million to be earned across multiple Statements of Work. All development will be performed at Biomerica's FDA‐licensed, ISO 13485 facility and revenue will be recognized on milestone acceptance; the engagement uses existing staff and equipment, providing near-term revenue visibility while the company continues to prioritize commercialization of its inFoods IBS diagnostic.